World Equity Group Inc. Invests $256,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

World Equity Group Inc. acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 2,420 shares of the medical equipment provider’s stock, valued at approximately $256,000.

Other institutional investors have also modified their holdings of the company. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth $25,000. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth $28,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth $35,000. Finally, Kentucky Trust Co purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth $39,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $106.00 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock has a market capitalization of $21.10 billion, a price-to-earnings ratio of 23.82, a PEG ratio of 1.95 and a beta of 1.02. The company has a 50-day simple moving average of $105.85 and a 200-day simple moving average of $107.44. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ZBH. Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Barclays reduced their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, JMP Securities reissued a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.